TABLE 1.

Selection criteria for urgent cases (priority A <4–5 weeks)

Selection criteria	Patients operated from Mar 24 to May 25
End of neoadjuvant treatment a	6
High‐risk cases with aggressive tumour biology for whom chemotherapy is contraindicated or was refused	4
Patients <70 years with luminal type B lesions where final pathology report is needed for further treatment decisions	25
Triple negative disease or HER2 positive <1.5 cm (T1N0)	5
Patients with extended or comedonic G3 in situ carcinoma with higher probability of invasive disease	12
Short interval (<48 months) locoregional recurrences	4

^a Treatment of choice in triple negative or HER2 positive lesions >1.5 cm or Luminal type B > 2 cm and/or N1 associated to high proliferation index (>20%).